Verisante Technology Updates on Reverse Takeover with SunRegen Healthcare

Verisante Technology, Inc. announced that SunRegen Healthcare AG has successfully completed a private placement of CHF1,333,333.40, equivalent to CAD$2,137,226. This pre-RTO private placement is part of the larger plan for Verisante to acquire SunRegen through a Reverse Takeover (RTO), indicating significant progress in this strategic acquisition.

The private placement, based on a pre-money valuation of CHF20,000,000, provides SunRegen with crucial funds for regulatory processes related to its lead pharmaceutical compound, SBC003, targeting neurodegenerative diseases. No finders' fees or commissions were involved in this transaction.

The completed deal aligns with the intended RTO, which may result in Verisante's full acquisition of SunRegen by mid-2025, with plans to expand the firm’s reach in the life sciences sector.